L. Ferris

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial†

Kelly N. Taylor, Constance M. Brown, B. Elewski, 2019, The British journal of dermatology.

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

D. Shrom, R. Burge, C. Griffiths, 2020 .

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.

S. Forman, C. Lynde, L. Kircik, 2023, JAMA dermatology.

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.

M. Lebwohl, Z. Draelos, M. Gooderham, 2022, JAMA.

Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials

M. Lebwohl, Z. Draelos, M. Gooderham, 2021, SKIN The Journal of Cutaneous Medicine.

Teledermatology isotretinoin management for moderate-to-severe acne reveals similar outcomes to in-person management: A retrospective study

J. English, S. Choudhary, A. James, 2023, JAAD International.